Hims & Hers Health Inc (NYSE: HIMS) started this week on a positive note after announcing its expansion into menopause-related treatments – a large and underserved market.
However, the rally is fading rather quickly. On Friday, the telehealth stock tanked another 15% as Andrew Dudum, the company’s chief executive, confirmed he’s sold over $11 million worth of its shares.
Including today’s decline, Hims & Hers stock is down roughly 30% versus its year-to-date high in February.
Why Dudum’s sales are bearish for Hims & Hers stock
While Dudum’s sale of HIMS stock was pre-scheduled, the optics are hard to ignore.
He unloaded more than 175,000 shares – including exercised options and vested restricted stock – just days after the company’s menopause expansion announcement.
This brings his total insider sales to over $40 million in the past three months. For a company still chasing consistent profitability, such aggressive insider selling raises red flags.
Investors often interpret insider sales as a lack of conviction in future growth, especially when they follow bullish news.
The timing has cast a shadow over Hims & Hers’ strategic narrative, suggesting even top leadership may be more focused on monetizing gains than riding the telehealth stock for the long term.
Why HIMS shares are unattractive heading into 2026
Beyond insider selling, Hims & Hers faces structural challenges that make its stock vulnerable.
The company trades at a premium forward price-to-earnings (P/E) multiple of 105 – significantly higher than its peers as well as the best-of-breed artificial intelligence (AI) stocks, even including Nvidia.
Thin margins and persistent net losses make that valuation even more concerning. HIMS’ direct-to-consumer model, while innovative, is expensive to scale – especially in a competitive telehealth landscape where customer acquisition costs are rising.
Meanwhile, regulatory scrutiny around digital prescriptions and compounded hormone therapies could also pose headwinds.
Investors should also note that the menopause market – while large – is fragmented and medically complex, requiring trust and clinical depth that HIMS has yet to fully establish.
With macro pressures mounting and profitability elusive, Hims & Hers’ lofty valuation looks increasingly difficult to defend.
How to play Hims & Hers at current levels
Hims & Hers has built its brand on sleek marketing and rapid product rollouts, but sustaining investor enthusiasm requires more than buzz.
The menopause pivot was a smart strategic move, yet the CEO’s stock sale has undermined its impact. As 2026 approaches, investors will be watching for signs of durable growth, margin expansion, and operational discipline.
Until then, Hims & Hers may remain a battleground stock – caught between retail optimism and institutional skepticism. For now, HIMS stock sell-off serves as a reminder that momentum fades fast when leadership signals mixed priorities.
The post Why Hims & Hers stock is failing to retain menopause gains and what comes next? appeared first on Invezz